4 10, 2022 Cytokines and lipid mediators of inflammation in lungs of SARS-CoV-2 infected miceNeal Evan Caminsky2022-11-15T09:14:07-05:00October 4, 2022|Funded Research Results, Pillar 3|
30 09, 2022 A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS -CoV-2 infectionNeal Evan Caminsky2022-11-15T09:14:05-05:00September 30, 2022|Funded Research Results, Pillar 3|
27 09, 2022 Human coronaviruses disassemble processing bodiesNeal Evan Caminsky2022-11-15T09:14:02-05:00September 27, 2022|Funded Research Results, Pillar 3|
26 09, 2022 Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variantsNeal Evan Caminsky2022-11-15T09:14:00-05:00September 26, 2022|Funded Research Results, Pillar 3|
6 09, 2022 A bivalent COVID-19 vaccine tailored to Omicron BA.1 is approved in Canada, however the need remains for a pan-coronavirus vaccineNeal Evan Caminsky2022-09-07T10:41:25-04:00September 6, 2022|Hot Topic|
23 08, 2022 Canadians can now get up-to-date information and answers to vaccination questions by meeting one-on-one with an immunization expertNeal Evan Caminsky2022-08-23T10:45:42-04:00August 23, 2022|Hot Topic|
9 08, 2022 Zoonotic Characteristics of mpox: Living Evidence ProfileNeal Evan Caminsky2023-01-18T15:47:06-05:00August 9, 2022|Funded Research Results, Pillar 9|
9 08, 2022 CoVaRR-Net Biobank ManagerNeal Evan Caminsky2022-08-09T14:49:50-04:00August 9, 2022|Careers|
8 08, 2022 Research Assistant in COVID-19Neal Evan Caminsky2022-08-09T15:08:54-04:00August 8, 2022|Careers|
27 07, 2022 As Canada Tackles its 7th COVID-19 Wave, 15 New Studies will Examine Solutions to Omicron and Other VariantsNeal Evan Caminsky2022-10-11T18:27:35-04:00July 27, 2022|News releases and statements|
